Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. Photo: Win McNamee/Getty Images
The vaccine that the National Institute of Allergy and Infectious Diseases (NIAID) and drugmaker Moderna have been developing to combat the coronavirus is ready to be tested on humans, NIAID director Anthony Fauci told the Wall Street Journal.
The state of play: The rapidly developed vaccine will be tested on 20–25 healthy volunteers in April to determine whether two doses will be safe and generate an immune response to protect against infection. Results will be available in July or August, Fauci told WSJ.
The big picture: The timing of the drug's development and expected clinical trial is extraordinary. "Going into a Phase One trial within three months of getting the sequence is unquestionably the world indoor record," Fauci said. "Nothing has ever gone that fast."
- However, it's uncertain whether the drug will work, considering that the gene-based technology it uses hasn't yet resulted in an approved human vaccine, per WSJ.
- A successful trial would also be followed by further studies and regulatory hurdles, Fauci said, meaning a coronavirus vaccine would not be ready for widespread distribution until at least next year.
Go deeper: Read Axios' full coverage of the coronavirus